OS Therapies IncorporatedOSTXNYSE
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 45.25% |
| Q2 2025 | 91.03% |
| Q1 2025 | 50.56% |
| Q4 2024 | -28.19% |
| Q3 2024 | 205.17% |
| Q2 2024 | 9.61% |
| Q1 2024 | -64.49% |
| Q4 2023 | 125.85% |
| Q3 2023 | 45341.82% |
| Q2 2023 | 31.72% |
| Q1 2023 | -31.34% |
| Q4 2022 | 0.00% |
| Q1 2022 | -1.19% |
| Q4 2021 | 0.00% |